Simple image-based no-wash method for quantitative detection of surface expressed CFTR
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R03 MH09360601, 5R01EB017268-02, P30 DK072506)
- Cystic Fibrosis Foundation (R883-CR07, FRIZZE13XXO)
This publication has 16 references indexed in Scilit:
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expressionScience Translational Medicine, 2014
- Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosisScience Translational Medicine, 2014
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences, 2011
- Influence of cell background on pharmacological rescue of mutant CFTRAmerican Journal of Physiology-Cell Physiology, 2010
- Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutantsBiochemical Journal, 2007
- The Binding Site for Channel Blockers That Rescue Misprocessed Human Long QT Syndrome Type 2 ether-a-gogo-related Gene (HERG) MutationsJournal of Biological Chemistry, 2002
- Traffic Jam: A Compendium of Human Diseases that Affect Intracellular Transport ProcessesTraffic, 2000
- Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT SyndromeJournal of Biological Chemistry, 1999
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999